Hongkongers to pay only HK$240 a year for leukaemia drug after system shake-up More than 400 cancer patients are set to benefit from Hong Kong health authorities’ decision to subsidise a leukaemia drug, reducing annual treatment costs from up to HK$500,000 (US$63,800) to just HK$240. The Hospital Authority said on Wednesday that it began subsidising the medication, Dasatinib, in April, with the government expected to allocate an additional HK$49 million in annual spending to help cover the cost. As part of the move, Dasatinib was reclassified from a “self-financed item” to...